Neuromodulation treatment for Parkinsonian Syndromes
Personalized Neuromodulation Treatment for Parkinson's Syndrome
This study is testing if new brain stimulation techniques can help people with Parkinsonian Syndromes feel better and manage their motor symptoms.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 40 Years to 80 Years |
| Sex | All |
| Sponsor | Ruijin Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai) |
| Trial ID | NCT06193278 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of neuromodulation techniques, specifically transcranial magnetic stimulation and transcranial direct current stimulation, in patients with Parkinsonian Syndromes characterized by motor dysfunction. The study will enroll sixty qualified patients who meet specific diagnostic criteria and will be conducted as a prospective, single-center, randomized, sham-controlled trial. The goal is to identify new therapeutic options that can alleviate symptoms and potentially slow disease progression in this patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 40 to 80 years diagnosed with Parkinsonian Syndromes who are stable on their current medication.
Not a fit: Patients with severe neuropsychiatric disorders, a history of significant neurological conditions, or those who have undergone certain previous treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide significant symptom relief and slow the progression of Parkinsonian Syndromes.
How similar studies have performed: Previous studies have shown promise in using neuromodulation techniques for similar conditions, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Compliance with the MDS revised clinical diagnostic criteria for Parkinsonian syndrome (2015 edition) * aged \>40 years and \<80 years, regardless of gender. * Patients were relatively stable during the study period and remained stable on medication * Good compliance, written informed consent, and consent for NIBS long-term intervention treatment Exclusion Criteria: * Patients with severe neuropsychiatric disorders or a previous history of severe neurologic conditions (e.g., epilepsy, cerebrovascular accident, etc.) or traumatic brain injury or brain surgery * inability to complete the questionnaire independently * Previous treatment with DBS or SCS; TMS or tDCS within 6 months * Severe physical illness and any physical condition that can precipitate epilepsy or intracranial hypertension, including cardiovascular and respiratory diseases * Installation of intracranial stents, pacemakers, coronary stents, cochlear implants, and other human implantable materials * is currently taking other investigational drugs or is participating in other clinical trials * Any other condition that the investigator believes makes him or her unsuitable for participation in this study.
Where this trial is running
Shanghai, Shanghai
- Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine — Shanghai, Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Jun Liu, Professor
- Email: jly0520@hotmail.com
- Phone: 64370045
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.